Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals, Inc. (MDGL): revenue, margins and EPS from its SEC filings, and Graham's reads as they come out.

From its filings

• Quarter ending 2026-06-30: revenue $364.3M (+71.2% vs a year earlier) · operating margin -15.5% · EPS -1.99 · filed 2026-07-30
• Quarter ending 2026-03-31: revenue $311.3M (+126.8% vs a year earlier) · operating margin -29.8% · EPS -3.25 · filed 2026-05-06
• Quarter ending 2025-12-31: revenue $321.1M (+210.8% vs a year earlier) · operating margin -18.6% · EPS -2.03 · filed 2026-02-19
• Quarter ending 2025-09-30: revenue $287.3M (+362.0% vs a year earlier) · operating margin -39.7% · EPS -4.01 · filed 2025-11-04
• Quarter ending 2025-06-30: revenue $212.8M (+1353.8% vs a year earlier) · operating margin -22.2% · EPS -1.50 · filed 2026-07-30
• Quarter ending 2025-03-31: revenue $137.3M · operating margin -57.8% · EPS -2.61 · filed 2026-05-06
• Quarter ending 2024-12-31: revenue $103.3M · operating margin -64.8% · EPS 2.09 · filed 2026-02-19
• Quarter ending 2024-09-30: revenue $62.2M · operating margin -187.1% · EPS -4.92 · filed 2025-11-04

Source: SEC EDGAR, 10-Q/10-K, as filed.